Stockholm, Sweden – 22 June 2022 – iCellate has recently finalized the expansion of its lab for the accredited service GeneMate®. GeneMate® is a service that is used to analyze an individual's hereditary risk of developing cancer.
iCellate Medical continues to grow! The transition to the new laboratory is complete: GeneMate® has a larger space for its operations, allowing for automation and higher capacity for clinical samples.
But it’s not just GeneMate® that benefits from more space at Industrivägen 1 – iCellate’s test to analysis of circulating tumor cells, CellMate®, receives an upgrade too to accommodate the ramp up of clinical studies.
- With so many clinical studies happening in parallel, it is great to have a dedicated space for the development of CellMate® services!”, says Sabina Botic, Head of Lab, who has been leading the transition to the new facilities.
GeneMate® is also celebrating 1 year since its SWEDAC accreditation. During the last audit, the new facilities and iCellate’s future plans for GeneMate® were discussed.
- It is very reassuring to have SWEDAC’s continued validation of our work” says Francisca Lameiras, Quality Director at iCellate.